Targets › PPP1CB
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2030.
Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase (PP1) is essential for cell division, it participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. (UniProt, P62140)
Open in Phaseline: the race on PPP1CB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AskBio | AB-1002 Protein phosphatase 1 catalytic subunit beta (PP1β) inhibitor delivered via intracoronary | PPP1CB | Phase 2 | Congestive Heart Failure | Dec 2030 |
Congestive Heart Failure (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.